The administration of a neutralizing anti-IFNAR antibody at day 2 after infection limited the ability of the host to control WNV replication and spread to target tissues, thus confirming a dominant antiviral effect of type I IFN during the early stages of pathogenesis. Here, IFNAR1 is linked to infection.